Overview

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD). We are studying the drug's effectiveness in treating depression, as well as its safety when it is added to another drug. Hypothesis A: There will be a difference in the percentage of responders in the two treatment conditions during phase 2; response rates will be higher for the ziprasidone group.

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

University of Alabama at Birmingham

Treatments:

Serotonin Uptake Inhibitors
Ziprasidone